Tatsuya Iwasaki

870 total citations
48 papers, 670 citations indexed

About

Tatsuya Iwasaki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Tatsuya Iwasaki has authored 48 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Tatsuya Iwasaki's work include Sarcoma Diagnosis and Treatment (17 papers), MicroRNA in disease regulation (9 papers) and Cancer-related molecular mechanisms research (6 papers). Tatsuya Iwasaki is often cited by papers focused on Sarcoma Diagnosis and Treatment (17 papers), MicroRNA in disease regulation (9 papers) and Cancer-related molecular mechanisms research (6 papers). Tatsuya Iwasaki collaborates with scholars based in Japan and Laos. Tatsuya Iwasaki's co-authors include Hiroshi Tsumura, Masanori Kawano, Ichiro Itonaga, Kazuhiro Tanaka, Masashi Miyazaki, Shinichi Ikeda, Naoto Shibuya, Hiroyuki Tsuchiya, Tomoyuki Kunishima and Junzo Nagashima and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Tatsuya Iwasaki

44 papers receiving 654 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tatsuya Iwasaki Japan 15 282 229 174 173 128 48 670
Ke Yuan China 12 324 1.1× 223 1.0× 60 0.3× 200 1.2× 40 0.3× 65 670
Sofia Spyridonidou Greece 15 298 1.1× 211 0.9× 232 1.3× 71 0.4× 80 0.6× 31 663
Cai Cheng China 19 429 1.5× 301 1.3× 94 0.5× 287 1.7× 37 0.3× 48 814
Daniel Caballero‐Díaz Spain 8 295 1.0× 123 0.5× 180 1.0× 73 0.4× 105 0.8× 9 706
Fangfang Duan China 15 317 1.1× 164 0.7× 182 1.0× 128 0.7× 209 1.6× 53 682

Countries citing papers authored by Tatsuya Iwasaki

Since Specialization
Citations

This map shows the geographic impact of Tatsuya Iwasaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tatsuya Iwasaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tatsuya Iwasaki more than expected).

Fields of papers citing papers by Tatsuya Iwasaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tatsuya Iwasaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tatsuya Iwasaki. The network helps show where Tatsuya Iwasaki may publish in the future.

Co-authorship network of co-authors of Tatsuya Iwasaki

This figure shows the co-authorship network connecting the top 25 collaborators of Tatsuya Iwasaki. A scholar is included among the top collaborators of Tatsuya Iwasaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tatsuya Iwasaki. Tatsuya Iwasaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kawano, Masanori, Tatsuya Iwasaki, Ichiro Itonaga, et al.. (2025). Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review. Japanese Journal of Clinical Oncology. 55(4). 313–326.
2.
Kataoka, Takashi, et al.. (2024). Preoperative abaloparatide plus zoledronate treatment accelerates femoral bone healing in rats following osteotomy. Journal of orthopaedic surgery. 32(3). 793565358–793565358.
3.
Sun, Hui, Masanori Kawano, Tatsuya Iwasaki, et al.. (2024). MicroRNA-329-3p inhibits the Wnt/β-catenin pathway and proliferation of osteosarcoma cells by targeting transcription factor 7-like 1. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 32(3). 463–476. 3 indexed citations
4.
Anan, Masaya, Masanori Kawano, Tatsuya Iwasaki, et al.. (2024). Gait analysis of a patient after femoral nerve and malignant soft tissue tumor resections: a case report. BMC Musculoskeletal Disorders. 25(1). 131–131.
5.
Kawano, Masanori, et al.. (2023). The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 31(5). 631–643. 3 indexed citations
6.
7.
8.
Tanaka, Kazuhiro, Masanori Hisaoka, Tsutomu Daa, et al.. (2021). Primary clear cell sarcoma of the femur: a unique case with RT-PCR and direct sequencing confirmation of EWSR1/ATF1 fusion gene. BMC Musculoskeletal Disorders. 22(1). 99–99. 2 indexed citations
9.
Matsumoto, Asami, Yosuke Suzuki, Kazuhiro Tanaka, et al.. (2021). Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application. Journal of Pharmaceutical and Biomedical Analysis. 206. 114348–114348. 7 indexed citations
10.
11.
Tanaka, Kazuhiro, Masanori Kawano, Tatsuya Iwasaki, Ichiro Itonaga, & Hiroshi Tsumura. (2020). A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma. BMC Cancer. 20(1). 379–379. 3 indexed citations
12.
Tanaka, Kazuhiro, Masanori Kawano, Tatsuya Iwasaki, Ichiro Itonaga, & Hiroshi Tsumura. (2019). Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation. BMC Cancer. 19(1). 56–56. 12 indexed citations
13.
Tanaka, Kazuhiro, Masanori Kawano, Tatsuya Iwasaki, Ichiro Itonaga, & Hiroshi Tsumura. (2019). A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas. PLoS ONE. 14(1). e0210671–e0210671. 11 indexed citations
14.
Kawano, Masanori, Kazuhiro Tanaka, Ichiro Itonaga, Tatsuya Iwasaki, & Hiroshi Tsumura. (2018). Interaction between human osteosarcoma and mesenchymal stem cells via an interleukin-8 signaling loop in the tumor microenvironment. Cell Communication and Signaling. 16(1). 13–13. 34 indexed citations
15.
Kawano, Masanori, Kazuhiro Tanaka, Ichiro Itonaga, Tatsuya Iwasaki, & Hiroshi Tsumura. (2016). MicroRNA-301a promotes cell proliferation via PTEN targeting in Ewing's sarcoma cells. International Journal of Oncology. 48(4). 1531–1540. 25 indexed citations
16.
Kawano, Masanori, et al.. (2015). microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells. Journal of Experimental & Clinical Cancer Research. 34(1). 76–76. 69 indexed citations
17.
Kawano, Masanori, Ichiro Itonaga, Tatsuya Iwasaki, & Hiroshi Tsumura. (2013). Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncology Reports. 29(3). 1001–1006. 43 indexed citations
18.
Kawano, Masanori, Ichiro Itonaga, Tatsuya Iwasaki, Hiroyuki Tsuchiya, & Hiroshi Tsumura. (2012). Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma. Clinical Orthopaedics and Related Research. 470(8). 2288–2294. 43 indexed citations
19.
Kunishima, Tomoyuki, Haruki Musha, Fumihiko Eto, et al.. (1997). A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clinical Therapeutics. 19(5). 1058–1066. 63 indexed citations
20.
Iwasaki, Tatsuya, et al.. (1982). Gel filtration and electrophoresis of soluble rice proteins extracted from long, medium, and short grain varieties.. Europe PMC (PubMed Central). 59(3). 192–195. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ke Yuan Breakdown of academic impact, for papers by Sofia Spyridonidou Breakdown of academic impact, for papers by Cai Cheng Breakdown of academic impact, for papers by Daniel Caballero‐Díaz Breakdown of academic impact, for papers by Fangfang Duan
Rankless by CCL
2026